Laterre PF, Berry SM, Blemings A, et al. - In this randomized, adaptive phase 2b/3 randomized clinical trial involving two parts, that involved 828 individuals with septic shock (most critical form, identified by vasodilatation and enhanced capillary permeability resulting in hypotension and tissue hypoxia) needing norepinephrine, researchers examined whether selepressin enhanced the outcome in septic shock. No notable variations in the primary endpoint or key secondary endpoints were seen. Cardiac arrhythmias, cardiac ischemia, mesenteric ischemia, and peripheral ischemia were adverse event rates involved. Therefore, in individuals with septic shock who were receiving norepinephrine, administration of selepressin, in comparison with placebo, did not lead to betterment in vasopressor- and ventilator-free days within 30 days. In order to assess the possible role of selepressin for other patient-centered outcomes in septic shock, further research would be required.